Nicholas Huntington

Money Moves

Part of the founding shareholder group

Japanese drugmaker Astellas Pharma now holds an exclusive option to license DAX-044, a preclinical cancer therapy from Melbourne-based Audax Biosciences. The deal is worth up to $1.34 billion, including $285 million in upfront and option exercise payments and up to $1.05 billion in milestones, before royalties.

Updated Oct 31